A randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging, efficacy and safety study of three doses of TCH346 (1mg, 5mg and 20mg daily) in patients with early Parkinson's disease
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2006
At a glance
- Drugs Omigapil (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 07 Dec 2006 New trial record.